The International Association for the Study of Lung Cancer (IASLC) is making people aware of a recent medical research development that may have benefits as regards possible new treatments for malignant pleural mesothelioma.
From this article, “Researchers find potential new target to treat malignant pleural mesothelioma”:
… researchers from the New York University Langone Medical Center looked at EPHB2 in 34 malignant pleural mesothelioma tumors , and found it significantly elevated in tumor tissue compared with matched normal peritoneum. They found EPHB2 overexpressed in all malignant pleural mesothelioma cell lines, but not in benign mesothelial cells. EPHB2 is also significantly elevated in malignant pleural mesothelioma tumor tissue compared with matched normal peritoneum.
Researchers believe, “targeting EPHB2 might provide a novel therapy to improve the prognosis in people suffering from malignant pleural mesothelioma….”
As pointed out elsewhere in that article:
Malignant mesothelioma is a rare asbestos-associated malignancy with limited therapeutic options. Despite advances in the treatment, the median survival remains 12 months from the time of diagnosis.
We will continue to watch for new possible mesothelioma treatments and report significant developments here.
Asbestos-Mesothelioma Case Evaluation Form
Free. Confidential. No Obligation.